tiprankstipranks
ThermoGenesis Holdings (THMO)
OTHER OTC:THMO
US Market

ThermoGenesis Holdings (THMO) AI Stock Analysis

Compare
330 Followers

Top Page

TH

ThermoGenesis Holdings

(OTC:THMO)

39Underperform
ThermoGenesis Holdings is facing significant financial and operational challenges, with negative equity, declining revenues, and liquidity issues. The absence of technical analysis data and meaningful valuation metrics further complicates the outlook. The neutral impact of the earnings call does not offset the overall negative financial performance.

ThermoGenesis Holdings (THMO) vs. S&P 500 (SPY)

ThermoGenesis Holdings Business Overview & Revenue Model

Company DescriptionThermoGenesis Holdings (THMO) is a biotechnology company that focuses on the development, commercialization, and licensing of automated technologies for cell processing and cell-based therapies. The company operates within the life sciences sector, providing a range of products and services designed to improve the efficiency and effectiveness of cell therapy manufacturing processes. Core products include automated cell separation systems, cryopreservation solutions, and other bioprocessing technologies aimed at supporting the growth of the regenerative medicine field.
How the Company Makes MoneyThermoGenesis Holdings generates revenue through the sale of its bioprocessing and cell therapy equipment, including automated cell separation systems and cryopreservation solutions. The company also earns income from licensing its proprietary technologies to other biotechnology firms and research institutions. Additionally, ThermoGenesis may engage in collaborations or partnerships where it provides its expertise and technology to support the development of new cell-based therapies, which can lead to milestone payments or royalties. The company's revenue is influenced by the growth of the regenerative medicine market and the adoption of automated solutions for cell processing.

ThermoGenesis Holdings Financial Statement Overview

Summary
ThermoGenesis Holdings is experiencing significant financial challenges with declining revenues, negative profit margins, and a concerning balance sheet marked by negative equity. Despite a slight improvement in free cash flow, liquidity and solvency issues persist.
Income Statement
40
Negative
ThermoGenesis Holdings has faced significant revenue decline with a negative revenue growth rate of -9.89% from 2022 to 2023. The net profit margin is negative, reflecting ongoing losses. Gross profit margin decreased to 20.44% in 2023, down from 25.85% in 2022, indicating increased cost pressures. EBIT and EBITDA margins are also negative, highlighting operational challenges. Overall, the income statement reveals declining revenues and persistent losses, suggesting financial difficulties.
Balance Sheet
30
Negative
The balance sheet shows a precarious financial position with negative stockholders' equity of -$1.67 million as of 2023, raising concerns about insolvency. The debt-to-equity ratio is not meaningful due to negative equity, indicating high leverage. The equity ratio is also negative, reflecting a weak capital structure. These factors suggest potential financial instability and risk to stakeholders.
Cash Flow
35
Negative
ThermoGenesis Holdings' cash flow statement indicates significant challenges, with negative free cash flow of -$5.45 million in 2023 compared to -$7.68 million in 2022, showing a slight improvement. The operating cash flow to net income ratio is not available, but persistently negative operating cash flows highlight liquidity issues. Overall, cash flow management remains a critical concern for the company.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
9.61M9.45M10.48M9.29M9.74M13.05M
Gross Profit
2.03M1.93M2.71M3.49M1.26M5.70M
EBIT
-8.12M-8.61M-6.19M-7.23M-8.89M-4.73M
EBITDA
-6.95M-7.74M-5.27M-6.60M-8.16M-4.73M
Net Income Common Stockholders
-14.74M-17.98M-11.27M-11.38M-16.35M-9.50M
Balance SheetCash, Cash Equivalents and Short-Term Investments
2.24M2.00M4.18M7.28M7.16M3.16M
Total Assets
15.63M11.23M19.39M20.65M20.86M15.21M
Total Debt
3.41M10.56M10.37M10.46M7.68M5.69M
Net Debt
1.18M8.56M6.19M3.18M517.00K2.54M
Total Liabilities
9.35M14.82M16.06M17.25M14.99M14.30M
Stockholders Equity
5.32M-1.67M4.30M3.83M5.80M386.00K
Cash FlowFree Cash Flow
-4.59M-5.45M-7.68M-6.71M-14.42M-3.44M
Operating Cash Flow
-3.61M-3.72M-7.28M-6.62M-14.39M-3.26M
Investing Cash Flow
-982.00K-1.73M-400.00K-93.00K-23.00K-182.00K
Financing Cash Flow
-82.00K3.28M4.59M6.83M17.42M4.20M

ThermoGenesis Holdings Risk Analysis

ThermoGenesis Holdings disclosed 46 risk factors in its most recent earnings report. ThermoGenesis Holdings reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

ThermoGenesis Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
$2.18B235.594.00%20.10%
54
Neutral
$789.76M-9.99%17.81%54.69%
52
Neutral
$271.51M-25.76%-2.09%-13.01%
51
Neutral
$1.05B-6.14%-20.89%83.44%
48
Neutral
$6.86B1.11-50.22%2.47%16.71%1.53%
43
Neutral
$248.78M-139.60%4.96%-29.29%
39
Underperform
$16.001078.28%-7.53%77.39%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
THMO
ThermoGenesis Holdings
0.02
-0.90
-97.83%
VCEL
Vericel
43.49
-6.93
-13.74%
AXGN
AxoGen
17.04
9.28
119.59%
BLFS
BioLife Solutions
22.44
4.93
28.16%
CYRX
CryoPort
5.44
-13.12
-70.69%
STIM
Neuronetics
3.60
-0.47
-11.55%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.